THE ROLE OF ESTROGEN IN PROMOTING TRIPLE NEGATIVE BREAST CANCER METASTASES IN THE BRAIN

Pauline Hoosepian-Mer, M.S., M.D. Candidate
With Diana Cittelly, PhD (PI) and Maria Jose Contreras-Zarate, PhD, Department of Pathology

ABSTRACT

Brain metastases (BM) from breast cancer portend a poor prognosis and a challenge to therapies. BM affect pre-menopausal women disproportionately and are more common in triple-negative (TN) breast cancers (TNBC), lacking estrogen receptor alpha, progesterone receptor, and HER2. Previous studies in the Cittelly lab demonstrated a role of estrogen in mediating breast cancer metastases in the brain through the upregulation of brain-derived neurotrophic factor (BDNF) via estradiol (E2)-stimulated astrocytes and subsequent activation of tropomyosin kinase receptor B (TrkB) in tumor cells. This project aims to:

1) Explore whether E2-depletion therapies can reduce brain metastatic burden
2) Elucidate transcription factor downstream of BDNF-TrkB which ultimately induce transcription to promote metastases in triple negative breast cancer cell lines.
3) Describe microglial recruitment and activation profiles at metastatic foci

To determine the role of estrogen-depletion to curtail/reduce metastatic burden in an in vivo model, qRT-PCR was conducted from DNA extracted from mouse brain hemispheres to quantify mCherry-expressing brain metastases. To investigate the activation of transcription factors glucocorticoid receptor/progesterone receptor (GR/PR) and peroxisome proliferator-activated receptor-α (PPAR) downstream of BDNF-TrkB, reporter gene assays were conducted using luciferase reporter plasmids transfected into triple negative cancer cell lines, MDA-MB-231 and BM-PDX-F2-7. Immunofluorescence staining was conducted using primary antibodies for TMEM 119 (general for microglia), CD16/32 (M1-profile microglia), and CD206 (M2-profile) to describe brain metastatic foci microglia recruitment and activation profiles.

Together, these aims will contribute to define the role of estrogen in the brain niche and the potential to integrate estrogen-depletion or TrkB inhibitors in metastatic breast cancer—to inform best practices and improve patient outcomes.

INTRODUCTION

Symptomatic brain metastases (BM) develop in 10–16% of patients with metastatic breast cancer. Prognosis of these patients is dismal with a survival varying from 4 to 18 months. Surveillance of brain metastases in breast cancer patients may be a better predictor of clinical outcome as compared to bone metastases. BM affect pre-menopausal women disproportionately with the incidence 53% versus 28% in postmenopausal women. BM are more common in triple-negative (TN) breast cancers (TNBC), lacking estrogen receptor alpha, progesterone receptor, and HER2. TMEM119 (Green), CD16/32 (M1-profile microglia), and CD206 (M2-profile). Increased microglial recruitment and activation profiles at metastatic foci. For PPAR, conditioned media groups previously demonstrating increased TF activation showed lower luminescence. For PPAR, conditioned media groups previously demonstrating increased TF activation showed lower luminescence. For PPAR, conditioned media groups previously demonstrating increased TF activation showed lower luminescence.

REFERENCES

1. Contreras-Zarate et al. investigated the role of estrogen in priming the brain niche for breast cancer metastases via paracrine signaling promoted by activated astrocytes and upregulation of brain-derived neurotrophic factor (BDNF). The subsequent activation of tropomyosin kinase receptor B (TrkB) in tumor cells promoted invasion, survival, and colonization via transcription factor activation. GR regulates many genes culminating in inflammation, cachexia, apoptosis, and cell survival. In ER-negative breast cancer including TNBC, high tumor expression of GR correlates with higher tumorigenicity, aggressiveness, chemotherapy-resistance, and overall worse prognosis. Activated microglia have been identified surrounding metastatic loci. The classical activation of macrophages, M1 activated, has been described as the pro-inflammatory phenotype which is anti-tumorigenic in effect, while the alternate activation profile, M2, is described as anti-inflammatory and, ultimately, tumor-supporting.

RESULTS

1) Can estrogen-withdrawal reduce brain metastases in a clinical setting (established mets + radiation)?
2) Reporter gene assays using luciferase plasmids MDA-MB-231 and BM-POX-F2-7
3) Immunofluorescence for TMEM 119 (general for microglia), CD16/32 (M1-profile microglia), and CD206 (M2-profile)

• Radiation dramatically altered brain metastatic growth
• Low tumor burden in all treatment groups (0 to 1000 metastatic cells per hemisphere despite expected metastatic burden of 10000-20000 cells per hemisphere)
• No statistically significant difference (α=0.05)

• Successfully transfected 231BR cell line
• Estrogen alone (E2), conditioned media from astrocytes induced by estrogen (CM-E2), or conditioned media from astrocytes with vehicle (CM-OH) had similar luminescence values.
• E2 alone increased transcription in TNBC cell lines.

• For PPAR, conditioned media groups previously demonstrating increased TF activation showed lower luminescence
• ANA-12 treatment group had the lowest luminescence, which was consistent with its effects of blocking BDNF-induced downstream pathways as a selective non-competitive antagonist of TrkB

CONCLUSIONS AND DISCUSSION

Radiation therapy at our current setting resulted in drastic attenuation of metastatic burden, in micro-metastases (<300 μm), yielding differences in qPCR too subtle to ascertain treatment differences requiring future experiments in radiation treatment adjustments, immunohistochemistry/immunofluorescence validation, or investigation in a larger or different tumor model (in process in syngeneic animal model). Future studies in radiation settings and the optimal therapeutic window warrant further investigation in targeted therapies aimed at relieving tumor burden. In a syngeneic model, there was no statistical difference in treatment arms with significant level α=0.05; however, hypothetically, to address underpowered study due to limited sample size (n=36) a significant level of 10% would render statistically significant difference between E2 and E2/WD-keratocyte samples—affording credence to a potentially highly relevant clinical difference.

The reporter gene assay outcomes were performed and optimized by two separate lab personnel. Concerns about yield and toxicity from the transfection were raised over the course of multiple experiments. MDA-MB-231 was shown to be highly sensitive to toxic compounds, which may have been introduced in the transfection reagents resulting in cellular damage and diminished reporter gene expression. Cell-based reporter gene assays are inherently difficult due to large number of potential targets, high level of crosstalk among signaling pathways which are difficult to narrow and confirm.

Furthermore, estradiol alone increased transcription in TNBC warranting investigation into the role of estrogen receptor beta, which has a previously established non-tumorigenic profile. The inactivated state of PPAR is attributed to the pro-tumorigenic profile in TNBC, and evidently, the activation may inhibit metastasis explaining the presumably contradictory decrease in luminescence. Exploring PPAR agonism may be a therapeutic potential.

FUTURE DIRECTIONS

• Identify and validate brain metastases and describe microglial subtypes (pro-versus anti-inflammatory) within tumor foci in triple negative breast cancer cell lines
• Syngeneic murine model was used to determine the ability of TNBC cell line to colonize the brain in the same inbred, immunocompetent mouse strain as the sourced tumor cells